The European Commission earlier this month granted the drug conditional marketing authorization, and Japan in May offered remdesivir regulatory approval.Gilead continues to study remdesivir treatment earlier in the illness, in outpatient settings, in an inhaled formulation (versus the current intravenous method), and in combination with other medicines.